Fresenius Medical Care AG (Fresenius Medical Care AG) Long-Term Capital Lease Obligation

: $3,848 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Fresenius Medical Care AG's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,848 Mil.

Fresenius Medical Care AG's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($4,129 Mil) to Sep. 2023 ($4,058 Mil) and declined from Sep. 2023 ($4,058 Mil) to Dec. 2023 ($3,848 Mil).

Fresenius Medical Care AG's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($4,619 Mil) to Dec. 2022 ($4,243 Mil) and declined from Dec. 2022 ($4,243 Mil) to Dec. 2023 ($3,848 Mil).

Fresenius Medical Care AG Long-Term Capital Lease Obligation Historical Data

The historical data trend for Fresenius Medical Care AG's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

4,518.11

4,724.00

4,618.99

4,242.52

3,848.41

Fresenius Medical Care AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																4,242.52	4,143.82	4,129.10	4,058.44	3,848.41

Fresenius Medical Care AG (NYSE:FMS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Fresenius Medical Care AG Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors